Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE Trial: Osimertinib in Positive PLasma T790M EGFR Mutant NSCLC
NCT02856893Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival Rate at 18 Months. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02856893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856893.